Skip to content
OpenCapital
Get started

Novanta NOVT Cash & Equivalents

Cash & Equivalents at other companies

Stryker logo
StrykerSYK
$2.88B+24.1%
Coherent logo
CoherentCOHR
$2.23B+36.9%
Intuitive Surgical logo
Intuitive SurgicalISRG
$2.05B-21.6%
Onto Innovation logo
Onto InnovationONTO
$252.25M+23.8%
Nordson logo
NordsonNDSN
$102.02M-21.6%
Globus Medical logo
Globus MedicalGMED
$560.95M+21.6%

Other financials

Income statement

See full
Revenue$257.7M+10.4%
Gross profit$113.6M+8.8%
Operating income$27.5M-15.1%
Net income$21.1M-0.5%
EPS (diluted)$0.51-13.6%

Balance sheet

See full
Total debt$291.3M-34.2%
Total equity$1.3B+70.3%
Total assets$1.8B+29.9%

Cash flow

See full
Operating cash flow$51.6M+62.9%
CapEx$4.1M-3.4%
Free cash flow$47.5M+73.2%

Valuation

See full
Market cap$5.53B-8.3%

Profitability

See full
Gross margin44.2%-0.5pp
Operating margin8.9%-3.5pp
Net margin5.3%-2.1pp
FCF margin6.8%-8.1pp

Returns & leverage

See full
Return on equity5.2%-4.6pp
Debt / equity0.2×-0.4×
Current ratio3.6×+1.0×

Where this comes from

Reported directly by Novanta in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: Novanta’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Novanta's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Novanta's cash & equivalents?
Novanta (NOVT) reported cash & equivalents of $388.8M in Q1 2026.
How has Novanta's cash & equivalents changed year-over-year?
Novanta's cash & equivalents increased by 266.6% year-over-year, from $106.05M to $388.8M.
What is the long-term trend for Novanta's cash & equivalents?
Over 5 years (2020 to 2025), Novanta's cash & equivalents has grown at a 24.9% compound annual growth rate (CAGR), from $125.05M to $380.87M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.